These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 17720663)

  • 1. Changes in facial fat in HIV-related lipoatrophy, wasting, and weight gain measured by magnetic resonance imaging.
    Paton NI; Yang Y; Tha NO; Sitoh YY
    HIV Clin Trials; 2007; 8(4):227-34. PubMed ID: 17720663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Objective assessment of facial lipoatrophy changes in a cohort of HIV-infected patients taking combination antiretroviral therapy.
    Yang Y; Yap M; Oo Tha N; Paton NI
    HIV Clin Trials; 2008; 9(6):399-406. PubMed ID: 19203905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Facial fat volume in HIV-infected patients with lipoatrophy.
    Yang Y; Sitoh YY; Oo Tha N; Paton NI
    Antivir Ther; 2005; 10(4):575-81. PubMed ID: 16038484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of three-dimensional laser scanning for the assessment of facial fat changes.
    Paton NI; Yang Y; Sitoh YY; Tha NO
    HIV Med; 2007 Nov; 8(8):498-503. PubMed ID: 17944682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipoatrophic men 44 months after the diagnosis of lipoatrophy are less lipoatrophic but more hypertensive.
    Bergersen BM; Sandvik L; Ellingsen I; Bruun JN
    HIV Med; 2005 Jul; 6(4):260-7. PubMed ID: 16011531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study.
    McComsey GA; Ward DJ; Hessenthaler SM; Sension MG; Shalit P; Lonergan JT; Fisher RL; Williams VC; Hernandez JE;
    Clin Infect Dis; 2004 Jan; 38(2):263-70. PubMed ID: 14699460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy.
    Grunfeld C; Saag M; Cofrancesco J; Lewis CE; Kronmal R; Heymsfield S; Tien PC; Bacchetti P; Shlipak M; Scherzer R;
    AIDS; 2010 Jul; 24(11):1717-26. PubMed ID: 20502316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitochondrial DNA depletion in adipose tissue of HIV-infected patients with peripheral lipoatrophy.
    Buffet M; Schwarzinger M; Amellal B; Gourlain K; Bui P; Prévot M; Deleuze J; Morini JP; Gorin I; Calvez V; Dupin N
    J Clin Virol; 2005 May; 33(1):60-4. PubMed ID: 15797366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How much fat loss is needed for lipoatrophy to become clinically evident?
    Podzamczer D; Ferrer E; Martínez E; Del Rio L; Rosales J; Curto J; Ribera E; Barrufet P; Llibre JM; Aranda M;
    AIDS Res Hum Retroviruses; 2009 Jun; 25(6):563-7. PubMed ID: 19500014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of discontinuing stavudine or protease inhibitor therapy on human immunodeficiency virus-related fat redistribution evaluated by dual-energy x-ray absorptiometry.
    Tavassoli N; Bagheri H; Sommet A; Delpierre C; Marion-Latard F; Massip P; Aquilina C; Bonnet E; Obadia M; Labau E; Montastruc JL; Bernard J
    Pharmacotherapy; 2006 Feb; 26(2):154-61. PubMed ID: 16466321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlates of risk of adipose tissue alterations and their modifications over time in HIV-1-infected women treated with antiretroviral therapy.
    Galli M; Ridolfo AL; Adorni F; Cappelletti A; Morelli P; Massetto B; Piazza M; Gianelli E; Vaccarezza M; Gervasoni C; Moroni M
    Antivir Ther; 2003 Aug; 8(4):347-54. PubMed ID: 14518704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correction of facial lipoatrophy using autologous fat transplants in HIV-infected adolescents.
    Dollfus C; Blanche S; Trocme N; Funck-Brentano I; Bonnet F; Levan P
    HIV Med; 2009 May; 10(5):263-8. PubMed ID: 19178590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of lipoatrophy and mitochondrial DNA content of blood and subcutaneous fat in HIV-1-infected patients randomly allocated to zidovudine- or stavudine-based therapy.
    van der Valk M; Casula M; Weverlingz GJ; van Kuijk K; van Eck-Smit B; Hulsebosch HJ; Nieuwkerk P; van Eeden A; Brinkman K; Lange J; de Ronde A; Reiss P
    Antivir Ther; 2004 Jun; 9(3):385-93. PubMed ID: 15259901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvements in cheek volume in lipoatrophic individuals switching away from thymidine nucleoside reverse transcriptase inhibitors.
    Benn P; Sauret-Jackson V; Cartledge J; Ruff C; Sabin CA; Moyle G; Linney A; Reilly G; Edwards SG
    HIV Med; 2009 Jul; 10(6):351-5. PubMed ID: 19490181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical lipoatrophy in HIV-1 patients on HAART is not associated with increased abdominal girth, hyperlipidaemia or glucose intolerance.
    Worm D; Kirk O; Andersen O; Vinten J; Gerstoft J; Katzenstein TL; Nielsen H; Pedersen C
    HIV Med; 2002 Oct; 3(4):239-46. PubMed ID: 12444941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disorders of fat partitioning in treated HIV-infection.
    Martínez E
    Best Pract Res Clin Endocrinol Metab; 2011 Jun; 25(3):415-27. PubMed ID: 21663836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weight loss after the first year of stavudine-containing antiretroviral therapy and its association with lipoatrophy, virological failure, adherence and CD4 counts at primary health care level in Kigali, Rwanda.
    van Griensven J; Zachariah R; Mugabo J; Reid T
    Trans R Soc Trop Med Hyg; 2010 Dec; 104(12):751-7. PubMed ID: 20889179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipodystrophy and reversal of facial lipoatrophy in perinatally HIV-infected children and adolescents after discontinuation of stavudine.
    Sawawiboon N; Wittawatmongkol O; Phongsamart W; Prasitsuebsai W; Lapphra K; Chokephaibulkit K
    Int J STD AIDS; 2012 Jul; 23(7):497-501. PubMed ID: 22844004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Magnetic resonance imaging evaluation of lipodystrophy in HIV-positive patients receiving highly active antiretroviral therapy.
    Eichler K; Bickel TM; Klauke S; Eisen J; Vogl TJ; Zangos S
    Int J STD AIDS; 2015 Jul; 26(8):582-9. PubMed ID: 25139003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study.
    Young J; Rickenbach M; Weber R; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
    Antivir Ther; 2005; 10(1):73-81. PubMed ID: 15751765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.